KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables (2016 - 2026)

Supernus Pharmaceuticals has reported Receivables over the past 15 years, most recently at $189.6 million for Q4 2025.

  • Quarterly Receivables rose 29.8% to $189.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.6 million through Dec 2025, up 29.8% year-over-year, with the annual reading at $189.6 million for FY2025, 29.8% up from the prior year.
  • Receivables was $189.6 million for Q4 2025 at Supernus Pharmaceuticals, up from $177.6 million in the prior quarter.
  • Over five years, Receivables peaked at $189.6 million in Q4 2025 and troughed at $127.1 million in Q1 2021.
  • The 5-year median for Receivables is $145.9 million (2024), against an average of $149.8 million.
  • Year-over-year, Receivables decreased 13.61% in 2023 and then grew 29.8% in 2025.
  • A 5-year view of Receivables shows it stood at $148.9 million in 2021, then grew by 11.12% to $165.5 million in 2022, then dropped by 12.9% to $144.2 million in 2023, then rose by 1.33% to $146.1 million in 2024, then grew by 29.8% to $189.6 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Receivables are $189.6 million (Q4 2025), $177.6 million (Q3 2025), and $146.2 million (Q2 2025).